UPDATE: Chardan On Emergent BioSolutions Post-Earnings: Firm Highlights FDA Allowing Co. To Resume Production Of JNJ Covid-19 Vaccine Bulk Substance At Bayview; Projects Co. To Generate Cash Flow From Operations In 2021 At $446M